SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.42 EUR
+0.12 (+0.78%)
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 22 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
In the past year 1SXP had a positive cash flow from operations.
1SXP had positive earnings in each of the past 5 years.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 1SXP (9.16%) is better than 81.82% of its industry peers.
1SXP's Return On Equity of 16.42% is amongst the best of the industry. 1SXP outperforms 86.36% of its industry peers.
The Return On Invested Capital of 1SXP (13.06%) is better than 86.36% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is above the industry average of 9.70%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
Looking at the Profit Margin, with a value of 14.85%, 1SXP is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
1SXP's Profit Margin has improved in the last couple of years.
The Operating Margin of 1SXP (18.95%) is better than 77.27% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 33.71%, 1SXP is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
1SXP has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
1SXP has a Debt to FCF ratio of 2.43. This is amongst the best in the industry. 1SXP outperforms 86.36% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.44
WACC9.05%
2.3 Liquidity
1SXP has a Current Ratio of 1.50. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.50 is fine compared to the rest of the industry. 1SXP outperforms 63.64% of its industry peers.
1SXP has a Quick Ratio of 1.12. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a better Quick ratio (1.12) than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.78% on average per year.
The Revenue has been growing slightly by 3.04% in the past year.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
The Earnings Per Share is expected to grow by 13.92% on average over the next years. This is quite good.
1SXP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.05% yearly.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y13.92%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y8.05%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.90, which indicates a correct valuation of 1SXP.
Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.19. 1SXP is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 15.03 indicates a correct valuation of 1SXP.
90.91% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
1SXP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.9 | ||
| Fwd PE | 15.03 |
4.2 Price Multiples
1SXP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1SXP is cheaper than 90.91% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 63.64% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.05 | ||
| EV/EBITDA | 8.8 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.77
PEG (5Y)1.15
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.18%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of 1SXP has falen by -24.41%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 0.48, 1SXP pays a better dividend. On top of this 1SXP pays more dividend than 90.91% of the companies listed in the same industry.
1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (1/9/2026, 7:00:00 PM)
15.42
+0.12 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.32B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target23.9 (54.99%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.21%
PT rev (3m)-20.68%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-10.89%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)-3.21%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.9 | ||
| Fwd PE | 15.03 | ||
| P/S | 2.35 | ||
| P/FCF | 66.05 | ||
| P/OCF | 12.91 | ||
| P/B | 2.6 | ||
| P/tB | 2.69 | ||
| EV/EBITDA | 8.8 |
EPS(TTM)0.97
EY6.29%
EPS(NY)1.03
Fwd EY6.65%
FCF(TTM)0.23
FCFY1.51%
OCF(TTM)1.19
OCFY7.75%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.77
PEG (5Y)1.15
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC9.05%
ROIC/WACC1.44
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y13.92%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y8.05%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y22.47%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 5.75% in the next year.